The Retatrutide + Cagrilintide research blend represents the broadest metabolic receptor coverage available in any single research combination: GLP-1R (appetite, insulin), GIPR (adipose insulin sensitivity), GCGR (thermogenesis, hepatic fat), and AMY1R (amylin-pathway satiety). Each receptor system contributes a mechanistically distinct input to energy balance regulation.
Retatrutide (Phase 2: −24.2% at 48 weeks) provides the triple GLP-1R/GIPR/GCGR agonism. Cagrilintide adds the AMY1R pathway — the same mechanism explored in Novo Nordisk’s CagriSema combination, which showed additive efficacy when combined with semaglutide (−15.6% vs ~7% for each alone). The hypothesis being tested: does AMY1R addition produce further additive benefit on top of triple GLP-1 agonism?
Specifications
Blend Components
Retatrutide + Cagrilintide
Retatrutide Mechanism
GLP-1R + GIPR + GCGR triple agonist
Cagrilintide Mechanism
AMY1R (amylin-1 receptor) agonist
Combined Receptor Coverage
GLP-1R · GIPR · GCGR · AMY1R (4 receptors)
Retatrutide Phase 2 Result
−24.2% weight reduction at 48 weeks (NEJM 2023)
Cagrilintide Phase 2 Result
−15.6% (CagriSema) at 32 weeks
QSC Purity
≥99% HPLC each component · Janoshik COA
Shipping
US Domestic: 2–4 days · International: 5–14 days
Frequently Asked Questions
What is the Retatrutide + Cagrilintide blend?
The Retatrutide + Cagrilintide blend is a research stack combining two complementary mechanisms: Retatrutide (GLP-1R+GIPR+GCGR triple agonist, −24.2% weight loss Phase 2) and Cagrilintide (AMY1R/amylin receptor agonist). Together they target four distinct receptors — GLP-1R, GIPR, GCGR, and AMY1R — covering all major metabolic appetite/energy pathways simultaneously.
Why research Retatrutide and Cagrilintide together?
The combination targets complementary receptor systems: Retatrutide handles GLP-1R (appetite), GIPR (adipose insulin sensitivity), and GCGR (thermogenesis/fat oxidation). Cagrilintide adds AMY1R (amylin pathway — area postrema, brainstem satiety signals). No existing approved drug targets all four receptors simultaneously. This makes the blend a unique research tool for studying maximum-breadth metabolic receptor activation.
What clinical data exists for this combination?
Individual components: Retatrutide Phase 2 (NEJM 2023): −24.2% at 48 weeks. Cagrilintide Phase 2 (CagriSema with semaglutide): −15.6% at 32 weeks. No published data exists for retatrutide + cagrilintide specifically — this is an active frontier in metabolic research. The hypothetical four-receptor combination represents the most comprehensive metabolic appetite suppression mechanistically achievable with current research compounds.
Where can I buy this research blend?
QSC stocks both Retatrutide and Cagrilintide individually at ≥99% HPLC purity with Janoshik COA. The blend is available as a pre-formulated research combination. Ships US Domestic in 2–4 business days. Research use only.
Research Use Only: Retatrutide + Cagrilintide Blend is sold by QSC strictly for in vitro laboratory research. Not for human or veterinary use. Not FDA approved for clinical application.
